Avanir Pharmaceuticals, Inc. (Nasdaq: AVNR) is a biopharmaceutical company focused bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.

The U.S. Food and Drug Administration (FDA) recently approved NUEDEXTA™ (dextromethorphan HBr and quinidine sulfate), for more information please visit www.nuedexta.com.

Avanir has conducted a Phase III study of AVP-923 in diabetic peripheral neuropathic (DPN) pain where the primary endpoints were successfully met.

Avanir has licensed macrophage migration inhibitory factor (MIF) program to Novartis International Pharmaceutical Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, abreva® (docosanol), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.